Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2022 | Role of neoadjuvant chemotherapy in patients undergoing bladder-sparing treatments

Aristotelis Bamias, MD, University of Athens, Athens, Greece, explores the role of neoadjuvant chemotherapy in patients undergoing bladder-sparing treatments, highlighting that it is currently not part of routine clinical practice, however its use is associated with delays in the initiation of radiotherapy. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.